​

Trevi Therapeutics Ownership | Who Owns Trevi Therapeutics?

OverviewForecastFinancialsChartTranscripts

Trevi Therapeutics Ownership Summary

Trevi Therapeutics is owned by 74.93% institutional investors, 15.68% insiders, and 9.40% retail investors. Nea management company is the largest institutional shareholder, holding 11.25% of TRVI shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.21% of its assets in Trevi Therapeutics shares.

TRVI Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockTrevi Therapeutics74.93%15.68%9.40%
SectorHealthcare Stocks 279.18%10.62%-189.80%
IndustryBiotech Stocks 63.96%10.74%25.30%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Nea management company11.37M11.25%$48.85M
Frazier life sciences management7.38M7.42%$22.00M
Viking global investors lp4.40M4.35%$18.13M
Rubric capital management lp4.21M4.16%$17.33M
Point72 asset management4.15M4.11%$17.10M
Blackrock funding, inc. /de3.93M3.89%$16.19M
Vanguard group3.51M3.47%$14.46M
Vivo capital3.49M3.45%$14.37M
Woodline partners lp3.21M3.18%$13.24M
Blackrock3.14M3.15%$9.34M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Acuta capital partners771.96K3.20%$3.18M
Ally bridge group (ny)781.49K2.76%$3.22M
Nea management company11.37M2.76%$48.85M
Rosalind advisors1.06M2.24%$4.38M
Bioimpact capital3.09M1.81%$12.75M
Opaleye management2.32M1.67%$9.55M
Vivo capital3.49M1.61%$14.37M
Frazier life sciences management7.38M1.03%$22.00M
Silverarc capital management734.23K0.66%$3.03M
Logos global management lp1.25M0.60%$5.15M

Top Buyers

HolderShares% AssetsChange
Point72 asset management4.15M0.04%4.15M
Siren2.91M0.53%2.91M
Woodline partners lp3.21M0.09%2.61M
Adage capital partners gp2.50M0.02%2.50M
Vivo capital3.49M1.61%1.88M

Top Sellers

HolderShares% AssetsChange
Vr adviser1.27M0.36%-2.16M
Logos global management lp1.25M0.60%-1.50M
Checkpoint capital---1.08M
Rubric capital management lp4.21M0.22%-821.80K
Ally bridge group (ny)781.49K2.76%-541.31K

New Positions

HolderShares% AssetsChangeValue
Point72 asset management4.15M0.04%4.15M$17.10M
Siren2.91M0.53%2.91M$11.97M
Adage capital partners gp2.50M0.02%2.50M$10.30M
Ikarian capital325.00K0.18%325.00K$1.34M
Two sigma investments, lp135.81K0.00%135.81K$559.52K

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-6.00
Steward partners investment advisory-25.00
Nisa investment advisors-84.00
Capital performance advisors llp-134.00
Federated hermes-598.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202514224.56%88,122,13510.86%741.21%9836.11%3233.33%
Dec 31, 202410710.31%67,554,27516.23%662.02%6634.69%2531.58%
Sep 30, 20249725.97%58,119,8883.96%571.82%4913.95%1926.67%
Jun 30, 202477-4.94%55,906,6878.43%562.07%4316.22%15-44.44%
Mar 31, 20248124.62%51,561,502-1.29%521.88%37-2.63%2792.86%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv2.24M2.21%-
iShares Russell 2000 ETF1.93M1.89%942.00
Vanguard US Total Market Shares ETF1.78M1.84%-
Vanguard Institutional Extnd Mkt Idx Tr1.03M1.01%1.97K
BlackRock Advantage Small Cap Core Instl793.27K0.78%701.29K
Fidelity Small Cap Index746.49K0.73%141.65K
Invesco Dorsey Wright Healthcare MomtETF427.18K0.42%-
iShares Russell 2000 Growth ETF403.47K0.40%-
Fidelity Extended Market Index356.94K0.37%55.41K
Vanguard Russell 2000 ETF372.70K0.37%25.09K

Recent Insider Transactions

DateNameRoleActivityValue
Mar 25, 2025SCIASCIA THOMAS Chief Scientific OfficerSell$17.36K
Mar 21, 2025GOOD JENNIFER L President & CEOSell$34.62K
Mar 10, 2025Simon Farrell Chief Commercial OfficerSell$31.10K
Mar 10, 2025Simon Farrell Chief Commercial OfficerSell$517.78K
Sep 06, 2024GOOD JENNIFER L President & CEOSell$12.78K

Insider Transactions Trends

DateBuySell
2025 Q1-4
2024 Q4--
2024 Q3-10
2024 Q2-4
2024 Q1--

TRVI Ownership FAQ

Who Owns Trevi Therapeutics?

Trevi Therapeutics shareholders are primarily institutional investors at 74.93%, followed by 15.68% insiders and 9.39% retail investors. The average institutional ownership in Trevi Therapeutics's industry, Biotech Stocks , is 63.96%, which Trevi Therapeutics exceeds.

Who owns the most shares of Trevi Therapeutics?

Trevi Therapeutics’s largest shareholders are Nea management company (11.37M shares, 11.25%), Frazier life sciences management (7.38M shares, 7.42%), and Viking global investors lp (4.4M shares, 4.35%). Together, they hold 23.02% of Trevi Therapeutics’s total shares outstanding.

Does Blackrock own Trevi Therapeutics?

Yes, BlackRock owns 3.15% of Trevi Therapeutics, totaling 3.14M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 9.34M$. In the last quarter, BlackRock increased its holdings by 759.41K shares, a 31.97% change.

Who is Trevi Therapeutics’s biggest shareholder by percentage of total assets invested?

Acuta capital partners is Trevi Therapeutics’s biggest shareholder by percentage of total assets invested, with 3.20% of its assets in 771.96K Trevi Therapeutics shares, valued at 3.18M$.

Who is the top mutual fund holder of Trevi Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Trevi Therapeutics shares, with 2.21% of its total shares outstanding invested in 2.24M Trevi Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools